Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation

Authors: James T Pearson, Mathew J Jenkins, Amanda J Edgley, Takashi Sonobe, Mandar Joshi, Mark T Waddingham, Yutaka Fujii, Daryl O Schwenke, Hirotsugu Tsuchimochi, Misa Yoshimoto, Keiji Umetani, Darren J Kelly, Mikiyasu Shirai

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Objectives

Activation of RhoA/Rho-kinase (ROCK) is increasingly implicated in acute vasospasm and chronic vasoconstriction in major organ systems. Therefore we aimed to ascertain whether an increase in ROCK activity plays a role in the deterioration of coronary vascular function in early stage diabetes.

Methods

Synchrotron radiation microangiography was used to determine in vivo coronary responses in diabetic (3 weeks post streptozotocin 65 mg/kg ip) and vehicle treated male Sprague–Dawley rats (n = 8 and 6). Changes in vessel number and calibre during vasodilator stimulation before and after blockade of nitric oxide synthase and cyclooxygenase were compared between rats. Acute responses to ROCK inhibitor, fasudil (10 mg/kg iv) was evaluated. Further, perivascular and myocardial fibrosis, arterial intimal thickening were assessed by histology, and capillary density, nitrotyrosine and ROCK1/2 expressions were evaluated by immunohistochemical staining.

Results

Diabetic rats had significantly elevated plasma glucose (P < 0.001 vs control), but did not differ in fibrotic scores, media to lumen ratio, capillary density or baseline visible vessel number or calibre. Responses to acetylcholine and sodium nitroprusside stimulation were similar between groups. However, in comparison to control rats the diabetic rats showed more segmental constrictions during blockade, which were not completely alleviated by acetylcholine, but were alleviated by fasudil. Further, second order vessel branches in diabetic rats were significantly more dilated relative to baseline (37% vs 12% increase, P < 0.05) after fasudil treatment compared to control rats, while visible vessel number increased in both groups. ROCK2 expression was borderline greater in diabetic rat hearts (P < 0.053).

Conclusions

We found that ahead of the reported decline in coronary endothelial vasodilator function in diabetic rats there was moderate elevation in ROCK expression, more widespread segmental constriction when nitric oxide and prostacyclin production were inhibited and notably, increased calibre in second and third order small arteries-arterioles following ROCK inhibition. Based on nitrotyrosine staining oxidative stress was not significantly elevated in early diabetic rats. We conclude that tonic ROCK mediated vasoconstriction contributes to coronary vasomotor tone in early diabetes.
Appendix
Available only for authorised users
Literature
1.
Prior JO, Quiñones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH, Sayre JW, Hsueh WA, Schelbert HR: Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation. 2005, 111 (18): 2291-2298. 10.1161/01.CIR.0000164232.62768.51.CrossRefPubMed
2.
Nahser PJ, Brown RE, Oskarsson H, Winniford MD, Rossen JD: Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation. 1995, 91 (3): 635-640. 10.1161/01.CIR.91.3.635.CrossRefPubMed
3.
Yonaha O, Matsubara T, Naruse K, Ishii H, Murohara T, Nakamura J, Amano T, Hotta N: Effects of reduced coronary flow reserve on left ventricular function in type 2 diabetes. Diabetes Res Clin Pract. 2008, 82 (1): 98-103. 10.1016/j.diabres.2008.06.020.CrossRefPubMed
4.
Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13 000 men and women with 20 years of follow-up. Arch Intern Med. 2004, 164 (13): 1422-1426. 10.1001/archinte.164.13.1422.CrossRefPubMed
5.
Nathan DM: Long-term complications of diabetes mellitus. New Engl J Med. 1993, 328 (23): 1676-1685. 10.1056/NEJM199306103282306.CrossRefPubMed
6.
Jenkins MJ, Edgley AJ, Sonobe T, Umetani K, Schwenke DO, Fujii Y, Brown RD, Kelly DJ, Shirai M, Pearson JT: Dynamic synchrotron imaging of diabetic rat coronary microcirculation in vivo. Arterioscler Thromb Vasc Biol. 2012, 32 (2): 370-377. 10.1161/ATVBAHA.111.237172.CrossRefPubMed
7.
Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A: Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001, 15 (6): 1062-1064.PubMed
8.
Shibuya M, Hirai S, Seto M, Satoh SI, Ohtomo E: Effects of fasudil in acute ischemic stroke: Results of a prospective placebo-controlled double-blind trial. J Neurol Sci. 2005, 238 (1–2): 31-39.CrossRefPubMed
9.
Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A: Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002, 105 (13): 1545-1547. 10.1161/hc1002.105938.CrossRefPubMed
10.
Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Eto Y, Morishige K, Matsumoto Y, Obara K, Nakayama K, Takahashi S, et al: Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm. Arterioscler Thromb Vasc Biol. 2003, 23 (12): 2209-2214. 10.1161/01.ATV.0000104010.87348.26.CrossRefPubMed
11.
Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, Tagawa T, Shimokawa H, Takeshita A, Sunagawa K: Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation. 2005, 111 (21): 2741-2747. 10.1161/CIRCULATIONAHA.104.510248.CrossRefPubMed
12.
Hamid SA, Bower HS, Baxter GF: Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol. 2007, 292 (6): H2598-H2606. 10.1152/ajpheart.01393.2006.CrossRefPubMed
13.
Xie Z, Su W, Guo Z, Pang H, Post SR, Gong MC: Up-regulation of CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular smooth muscle cells. Cardiovasc Res. 2006, 69 (2): 491-501. 10.1016/j.cardiores.2005.11.002.CrossRefPubMed
14.
15.
Arita R, Hata Y, Nakao S, Kita T, Miura M, Kawahara S, Zandi S, Almulki L, Tayyari F, Shimokawa H, et al: Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes. 2009, 58 (1): 215-226. 10.2337/db08-0762.PubMedCentralCrossRefPubMed
16.
Budzyn K, Marley PD, Sobey CG: Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci. 2006, 27 (2): 97-104. 10.1016/j.tips.2005.12.002.CrossRefPubMed
17.
Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A: Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol. 2003, 41 (1): 15-19. 10.1016/S0735-1097(02)02632-3.CrossRefPubMed
18.
Satoh SI, Utsunomiya T, Tsurui K, Kobayashi T, Ikegaki I, Sasaki Y, Asano T: Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 2001, 69 (12): 1441-1453. 10.1016/S0024-3205(01)01229-2.CrossRefPubMed
19.
Yada T, Shimokawa H, Hiramatsu O, Kajita T, Shigeto F, Tanaka E, Shinozaki Y, Mori H, Kiyooka T, Katsura M, et al: Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo. J Am Coll Cardiol. 2005, 45 (4): 599-607. 10.1016/j.jacc.2004.10.053.CrossRefPubMed
20.
Didion SP, Lynch CM, Baumbach GL, Faraci FM: Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes. Stroke. 2005, 36 (2): 342-347. 10.1161/01.STR.0000152952.42730.92.CrossRefPubMed
21.
Kobayashi N, Horinaka S, Mita SI, Nakano S, Honda T, Yoshida K, Kobayashi T, Matsuoka H: Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res. 2002, 55 (4): 757-767. 10.1016/S0008-6363(02)00457-1.CrossRefPubMed
22.
Schwenke DO, Pearson JT, Sonobe T, Ishibashi-Ueda H, Shimouchi A, Kangawa K, Umetani K, Shirai M: Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension. J Appl Physiol. 2011, 110 (4): 901-908. 10.1152/japplphysiol.01318.2010.CrossRefPubMed
23.
Hagikura K, Fukuda N, Yokoyama S, Yuxin L, Kusumi Y, Matsumoto T, Ikeda Y, Kunimoto S, Takayama T, Jumabay M: Low invasive angiogenic therapy for myocardial infarction by retrograde transplantation of mononuclear cells expressing the VEGF gene. Int J Cardiol. 2010, 142 (1): 56-64. 10.1016/j.ijcard.2008.12.108.CrossRefPubMed
24.
Fiordaliso F, Cuccovillo I, Bianchi R, Bai A, Doni M, Salio M, De Angelis N, Ghezzi P, Latini R, Masson S: Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci. 2006, 79 (2): 121-129. 10.1016/j.lfs.2005.12.036.CrossRefPubMed
25.
Patumraj S, Tewit S, Amatyakul S, Jariyapongskul A, Maneesri S, Kasantikul V, Shepro D: Comparative effects of garlic and aspirin on diabetic cardiovascular complications. Drug Deliv. 2000, 7 (2): 91-96. 10.1080/107175400266650.CrossRefPubMed
26.
Jesmin S, Zaedi S, Shimojo N, Iemitsu M, Masuzawa K, Yamaguchi N, Mowa CN, Maeda S, Hattori Y, Miyauchi T: Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts. Am J Physiol Endocrinol Metab. 2007, 292 (4): E1030-E1040.CrossRefPubMed
27.
Tawfik HE, El-Remessy AB, Matragoon S, Ma G, Caldwell RB, Caldwell RW: Simvastatin improves diabetes-induced coronary endothelial dysfunction. J Pharmacol Exp Ther. 2006, 319 (1): 386-395. 10.1124/jpet.106.106823.CrossRefPubMed
28.
El-Remessy AB, Tawfik HE, Matragoon S, Pillai B, Caldwell RB, Caldwell RW: Peroxynitrite mediates diabetes-induced endothelial dysfunction: possible role of Rho kinase activation. Exp Diabetes Res. 2010, 2010: 247861.PubMedCentralCrossRefPubMed
29.
Nacci C, Tarquinio M, De Benedictis L, Mauro A, Zigrino A, Carratù MR, Quon MJ, Montagnani M: Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature. Endocrinology. 2009, 150 (2): 849-861.PubMedCentralCrossRefPubMed
30.
Leo CH, Joshi A, Woodman OL: Short-term type 1 diabetes alters the mechanism of endothelium-dependent relaxation in the rat carotid artery. Am J Physiol Heart Circ Physiol. 2010, 299 (2): H502-H511. 10.1152/ajpheart.01197.2009.CrossRefPubMed
31.
Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T, Egashira K, Ikegaki I, et al: Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999, 43 (4): 1029-1039. 10.1016/S0008-6363(99)00144-3.CrossRefPubMed
32.
Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S: ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996, 392 (2): 189-193. 10.1016/0014-5793(96)00811-3.CrossRefPubMed
33.
Nuno DW, Harrod JS, Lamping KG: Sex-dependent differences in Rho activation contribute to contractile dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2009, 297 (4): H1469-H1477. 10.1152/ajpheart.00407.2009.CrossRefPubMed
34.
Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD: Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol. 2003, 138 (5): 757-766. 10.1038/sj.bjp.0705109.PubMedCentralCrossRefPubMed
35.
Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, Mazzolai L, Hayoz D, Ruffieux J, Rusconi S, Montani JP, et al: Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: Implications for atherosclerotic endothelial dysfunction. Circulation. 2004, 110 (24): 3708-3714. 10.1161/01.CIR.0000142867.26182.32.CrossRefPubMed
36.
Matsumoto T, Kobayashi T, Ishida K, Taguchi K, Kamata K: Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes. Br J Pharmacol. 2010, 160 (5): 1092-1104. 10.1111/j.1476-5381.2010.00753.x.PubMedCentralCrossRefPubMed
37.
Zou MH, Cohen RA, Ullrich V: Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium. 2004, 11 (2): 89-97. 10.1080/10623320490482619.CrossRefPubMed
38.
Nitenberg A, Valensi P, Sachs R, Cosson E, Attali JR, Antony I: Prognostic value of epicardial coronary artery constriction to the cold pressor test in Type 2 diabetic patients with angiographically normal coronary arteries and no other major coronary risk factors. Diabetes Care. 2004, 27 (1): 208-215. 10.2337/diacare.27.1.208.CrossRefPubMed
39.
Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y, Higo T, Egashira K, Takahashi S, Kaibuchi K, et al: Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β. Circulation. 2000, 101 (11): 1319-1323. 10.1161/01.CIR.101.11.1319.CrossRefPubMed
40.
Sato M, Tani E, Fujikawa H, Kaibuchi K: Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res. 2000, 87 (3): 195-200. 10.1161/01.RES.87.3.195.CrossRefPubMed
41.
Inokuchi K, Ito A, Fukumoto Y, Matoba T, Shiose A, Nishida T, Masuda M, Morita S, Shimokawa H: Usefulness of fasudil, a Rho-kinase inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery. J Cardiovasc Pharmacol. 2004, 44 (3): 275-277. 10.1097/01.fjc.0000134775.76636.3f.CrossRefPubMed
42.
Matsumoto T, Kajiya F: Coronary microcirculation: Physiology and mechanics. Fluid Dynam Res. 2005, 37 (1–2 SPEC. ISS): 60-81.CrossRef
43.
Failli P, Alfarano C, Franchi-Micheli S, Mannucci E, Cerbai E, Mugelli A, Raimondi L: Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats. Cardiovasc Diabetol. 2009, 8: 32-10.1186/1475-2840-8-32.PubMedCentralCrossRefPubMed
44.
Miao L, Calvert JW, Tang J, Zhang JH: Upregulation of small GTPase RhoA in the basilar artery from diabetic (mellitus) rats. Life Sci. 2002, 71 (10): 1175-1185. 10.1016/S0024-3205(02)01827-1.CrossRefPubMed
45.
Bailey SR, Mitra S, Flavahan S, Flavahan NA: Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol. 2005, 289 (1 58–1): H243-H250.CrossRefPubMed
46.
Oi K, Shimokawa H, Hiroki J, Uwatoku T, Abe K, Matsumoto Y, Nakajima Y, Nakajima K, Takeichi S, Takeshita A: Remnant lipoproteins from patients with sudden cardiac death enhance coronary vasospastic activity through upregulation of Rho-kinase. Arterioscler Thromb Vasc Biol. 2004, 24 (5): 918-922. 10.1161/01.ATV.0000126678.93747.80.CrossRefPubMed
47.
Zhang FL, Ye C, Li G, Ding W, Zhou W, Zhu H, Chen G, Luo T, Guang M, Liu Y, et al: The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp Anim. 2003, 52 (5): 401-407. 10.1538/expanim.52.401.CrossRefPubMed
48.
Tickerhoof MM, Farrell PA, Korzick DH: Alterations in rat coronary vasoreactivity and vascular protein kinase C isoforms in Type 1 diabetes. Am J Physiol Heart Circ Physiol. 2003, 285: H2694-H2703.CrossRefPubMed
49.
Lin G, Craig GP, Zhang L, Yuen VG, Allard M, McNeill JH, MacLeod KM: Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc Res. 2007, 75 (1): 51-58. 10.1016/j.cardiores.2007.03.009.CrossRefPubMed
50.
Nagareddy PR, Soliman H, Lin G, Rajput PS, Kumar U, McNeill JH, MacLeod KM: Selective Inhibition of Protein Kinase C β2 Attenuates Inducible Nitric Oxide Synthase–Mediated Cardiovascular Abnormalities in Streptozotocin-Induced Diabetic Rats. Diabetes. 2009, 58 (10): 2355-2364. 10.2337/db09-0432.PubMedCentralCrossRefPubMed
51.
Soliman H, Craig GP, Nagareddy P, Yuen VG, Lin G, Kumar U, McNeill JH, MacLeod KM: Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats. Cardiovasc Res. 2008, 79 (2): 322-330. 10.1093/cvr/cvn095.CrossRefPubMed
52.
Kizub I, Pavlova O, Johnson C, Soloviev A, Zholos A: Rho kinase and protein kinase C involvement in vascular smooth muscle myofilament calcium sensitization in arteries from diabetic rats. Br J Pharmacol. 2010, 159 (8): 1724-1731. 10.1111/j.1476-5381.2010.00666.x.PubMedCentralCrossRefPubMed
53.
Shirai M, Schwenke DO, Eppel GA, Evans RG, Edgley AJ, Tsuchimochi H, Umetani K, Pearson JT: Synchrotron-based angiography for investigation of the regulation of vasomotor function in the microcirculation in vivo. Clin Exp Pharmacol Physiol. 2009, 36 (1): 107-116. 10.1111/j.1440-1681.2008.05073.x.CrossRefPubMed
54.
Zhou H, Li YJ, Wang M, Zhang LH, Guo BY, Zhao ZS, Meng FL, Deng YG, Wang RY: Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes. Acta Pharmacol Sin. 2011, 32 (8): 999-1008. 10.1038/aps.2011.54.PubMedCentralCrossRefPubMed
55.
Ichinomiya T, Cho S, Higashijima U, Matsumoto S, Maekawa T, Sumikawa K: High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channels. Cardiovasc Diabetol. 2012, 11: 28-10.1186/1475-2840-11-28.PubMedCentralCrossRefPubMed
56.
Li H, Peng W, Jian W, Li Y, Li Q, Li W, Xu Y: ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion. Cardiovasc Diabetol. 2012, 11: 65-10.1186/1475-2840-11-65.PubMedCentralCrossRefPubMed
57.
Wu DJ, Xu JZ, Wu YJ, Jean-Charles L, Xiao B, Gao PJ, Zhu DL: Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice. Atherosclerosis. 2009, 207 (1): 68-73. 10.1016/j.atherosclerosis.2009.04.025.CrossRefPubMed
Metadata
Title
Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation
Authors
James T Pearson
Mathew J Jenkins
Amanda J Edgley
Takashi Sonobe
Mandar Joshi
Mark T Waddingham
Yutaka Fujii
Daryl O Schwenke
Hirotsugu Tsuchimochi
Misa Yoshimoto
Keiji Umetani
Darren J Kelly
Mikiyasu Shirai
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-111

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue

Original investigation

Association between circulating leukocyte subtype counts and carotid intima-media thickness in Japanese subjects with type 2 diabetes

Original investigation

Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns

Original investigation

Myocardial impulse propagation is impaired in right ventricular tissue of Zucker Diabetic Fatty (ZDF) rats

Original investigation

Type 1 diabetes mellitus abrogates compensatory augmentation of myocardial neuregulin-1β/ErbB in response to myocardial infarction resulting in worsening heart failure

Original investigation

Metabolic, hemodynamic and structural adjustments to low intensity exercise training in a metabolic syndrome model

Original investigation

The adaptability of red blood cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits